Navigation Links
Spectros T-Stat Shown to Be Earliest Available Method for Detection of Surgical Skin Flap Compromise After Surgery
Date:10/5/2011

PORTOLA VALLEY, Calif., Oct. 5, 2011 /PRNewswire/ -- In an independent study published in the Journal of Reconstructive Microsurgery, researchers at the University of Texas Health Science Center San Antonio have found that the Spectros T-Stat® oximeter responds earliest to compromised blood flow during reconstructive microsurgery when compared clinically to other available monitors.

This landmark study by Dr. Cornejo and colleagues is important as compromised blood flow to microvascular free flaps causes irreversible damage and/or complete loss of the flap, resulting in longer hospital stays and additional costs to both hospital and patient. While a detailed economic analysis was not an endpoint of this study, earlier detection of tissue compromise results in an improved patient outcome and overall reduced hospital costs.

"These are very strong results supporting the superiority of the T-Stat VLS Oximeter," noted CEO and physician Dr. David Benaron, "This study provides solid evidence that the Spectros broadband light technologies offer the earliest and most sensitive detection of tissue compromise, and suggests that all reconstructive surgery cases can benefit from T-Stat monitoring."

Spectros oximeters are currently the only broadband solid-state tissue oximeters on the market in the U.S. and Europe. T-Stat patented broadband technology provides continuous and real-time absolute measurement of tissue hemoglobin oxygenation using 100s of wavelengths of light, a key advantage over competing oximeter product lines that only use 2 or 4 wavelengths. An expanded array of broadband sensors, including NIRS Continuum® cerebral sensor, is currently in testing, with FDA and EU approval anticipated in 2012.

In reconstructive surgery, T-Stat competes with T.Ox® oximeters marketed by ViOptix and Doppler marketed by Cook Medical. In critical care, the ICU and O.R., T-Stat competes with INVOS® oximeters marketed by Covidien and FORE-SIGHT® oximeters marketed by CAS Medical.

About Spectros

Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. T-Stat was the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue, and remains the only commercially-available tissue oximeter that utilizes state-of-the-art broadband spectroscopy. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.

Spectros also develops molecular diagnostic tools for breast and prostate cancer, including ProstaFluor® contrast agents, currently entering phase I/II clinical trials supported by the National Cancer Institute.  

(Note:  Forward-looking statements are intended as a guide only, and do not constitute an offer for investment. Certain applications described above have not been reviewed by the FDA or European agencies, and are therefore labeled "for investigational use only." T-Stat and Continuum are trademarks of Spectros. INVOS is a trademark of Somanetics and Covidien. FORE-SIGHT is a trademark of CAS Medical).

For further information, visit www.spectros.com.


'/>"/>
SOURCE Spectros
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
2. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
3. Spectros Corp. Enters Into Optical Biotechnology Patent Sale Agreement With Philips Electronics N.V.
4. Spectros Presents at the Pediatric Academic Societies (PAS) National Conference 2010
5. ICAP Ocean Tomo Offers IP Portfolio of Near-Infrared Spectroscopy Technology
6. Spectros Presents New Clinical Studies Using T-Stat VLS Tissue Oximeter at Anesthesiology 2010
7. Spectros White LED Patent Scope Affirmed In U.S. Patent Office Reexamination
8. Spectros Corporation Sales and Licensing Revenue Up 32% in 2010
9. Spectros Corporation Introduces Continuum®, a Broadband Infrared Sensor for Brain and Gut Oximetry
10. Spectros Corporation Year-To-Date Oximeter Sales Revenue Up 51% in First Half of 2011
11. RediClinic Offers Affordable New Plan Clinically Shown to Double a Persons Chance to Stop Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016  Nevro Corp. (NYSE: NVRO ), ... evidence-based solutions for the treatment of chronic pain, today ... has filed a lawsuit for patent infringement.  The lawsuit, ... District of Delaware , alleges that ... to stimulation leads, batteries, and telemetry units. ...
(Date:12/9/2016)... 2016 MSD, a nationally recognized supplier of ... alternate site health care facilities, announced today that it ... ("First Choice"), a privately held national distributor of medical ... home health segments. We would like to welcome First ... compelling transaction will deliver significant and immediate value to ...
(Date:12/9/2016)... December 9, 2016 External ... Single-Chamber ICD, Dual-Chamber ICD, Cardiac Resynchronization Therapy Defibrillators ... Cardioverter Defibrillators The global defibrillators ... CAGR of 5.3% from 2016-2020 and CAGR of ... grow at a CAGR of 5.2% from 2016 ...
Breaking Medicine Technology:
(Date:12/10/2016)... ... 10, 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) ... other healthcare organizations to promote diabetes education at the World Diabetes Day observance. ... of speakers from around the Commonwealth of Pennsylvania. Speakers included Dr. Renu ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... planning assistance from offices in Pasco and Richland, is initiating a charity drive ... serious injuries resulting from a recent automobile collision. , On October 29th ...
(Date:12/9/2016)... ... 2016 , ... The Justin Veatch Fund announced Thursday that ... film Whispering Spirits and its discussion guide for use by all of ... in the war against teen drug abuse. NCADD is the oldest anti-addiction advocacy ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... Ball at The Pierre Hotel in New York, NY, on December 3rd, to ... dignitaries and physicians attended the annual event, which raised over $1 million - ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... become Quality Insights beginning January 1, 2017. The name change aligns the ... to measuring and improving health care quality. , “We are very proud of ...
Breaking Medicine News(10 mins):